Michael Robert Lewis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Robert Lewis has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Fang Jia
Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, 65211
10 shared publicationsFabio Gallazzi
Molecular Imaging and Theranostics Center, University of Missouri, Columbia, MO, United States of America; Molecular Interactions Core, University of Missouri, Columbia, MO, United States of America
7 shared publications- Carolyn J. Anderson
Department of Chemistry, University of Missouri, Columbia, Missouri
4 shared publications - Heather M. Hennkens
Department of Chemistry , University of Missouri , Columbia , 65211 , MO , USA
4 shared publications - Jeffrey N. Bryan
Department of Veterinary Medicine and Surgery University of Missouri Columbia Missouri USA
4 shared publications - Silvia Sabine Jurisson
Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United States
4 shared publications
Latest Publications
- Open Access
Pharmacokinetic-Modifying Linker Design Modulates Performance of Multivalent PSMA/GRPR-Cell-Targeting 177Lu Radiopharmaceuticals
Background/Objectives: A series of PSMA/GRPR-targeting compounds were selected based on modifications to their respective pharmacokinetic-modifying linking groups and the structure of the PSMA-binding moiety, to examine how these alterations impact binding affinity and specificity for preclinical prostate cancer models. Methods: The multi-receptor targeting heterodimers PSMA/2PSMA-X-DOTA-Y-BBN (where X is 6-aminohexanoic acid (6AHX) or polyethylene glycol-4 (PEG4) and Y is either 8-aminooctanoic acid (8AOC) or carboxy piperidine (CP)) were radiolabeled with the theranostic isotope [177Lu]Lu. Each heterodimer construct was evaluated through characterization, stability, whole-cell in vitro studies, biodistribution in tumor-bearing mice, and in vivo small animal SPECT/CT molecular imaging. Results: In vitro evaluation of 2PSMA-6AHX-DOTA-8AOC-BBN demonstrated moderate IC50 values of 200 ± 20 nM in LNCaP cells and 21 ± 1 nM in PC3 cells. Subsequent biodistribution studies demonstrated selective tumor uptake at 4 h post-intravenous injection with uptake of 9.52 ± 2.59%ID/g in GRPR[+] PC3 tumors and 6.37 ± 0.64%ID/g in PSMA[+] PC3-PIP tumors. At 24 h post-injection, high tumor-to-blood ratios (874.0 ± 276 in PC3 and 344.3 ± 85 in PC3-PIP) and tumor-to-muscle ratios (739.8 ± 277 in PC3 and 403.5 ± 66 in PC3-PIP) were observed, further supporting the theranostic feasibility of the radiolabeled heterodimer. Small animal SPECT/CT imaging confirmed tumor targeting specificity of the heterobivalent peptide. Conclusions: Evaluation in PSMA/GRPR-expressing tumor models identified 2PSMA-6AHX-DOTA-8AOC-BBN as a leading candidate, having enhanced tumor uptake and favorable pharmacokinetics in tumor-bearing mice. These investigations advance structure–activity relationship understanding and support heterobivalent radiopharmaceuticals for precision imaging and targeted prostate cancer therapy.
Open AccessPharmacokinetic-Modifying Linker Design Modulates Performance of Multivalent PSMA/GRPR-Cell-Targeting 177Lu Radiopharmaceuticals
Background/Objectives: A series of PSMA/GRPR-targeting compounds were selected based on modifications to their respective pharmacokinetic-modifying linking groups and the structure of the PSMA-binding moiety, to examine how these alterations impact binding affinity and specificity for preclinical prostate cancer models. Methods: The multi-receptor targeting heterodimers PSMA/2PSMA-X-DOTA-Y-BBN (where X is 6-aminohexanoic acid (6AHX) or polyethylene glycol-4 (PEG4) and Y is either 8-aminooctanoic acid (8AOC) or carboxy piperidine (CP)) were radiolabeled with the theranostic isotope [177Lu]Lu. Each heterodimer construct was evaluated through characterization, stability, whole-cell in vitro studies, biodistribution in tumor-bearing mice, and in vivo small animal SPECT/CT molecular imaging. Results: In vitro evaluation of 2PSMA-6AHX-DOTA-8AOC-BBN demonstrated moderate IC50 values of 200 ± 20 nM in LNCaP cells and 21 ± 1 nM in PC3 cells. Subsequent biodistribution studies demonstrated selective tumor uptake at 4 h post-intravenous injection with uptake of 9.52 ± 2.59%ID/g in GRPR[+] PC3 tumors and 6.37 ± 0.64%ID/g in PSMA[+] PC3-PIP tumors. At 24 h post-injection, high tumor-to-blood ratios (874.0 ± 276 in PC3 and 344.3 ± 85 in PC3-PIP) and tumor-to-muscle ratios (739.8 ± 277 in PC3 and 403.5 ± 66 in PC3-PIP) were observed, further supporting the theranostic feasibility of the radiolabeled heterodimer. Small animal SPECT/CT imaging confirmed tumor targeting specificity of the heterobivalent peptide. Conclusions: Evaluation in PSMA/GRPR-expressing tumor models identified 2PSMA-6AHX-DOTA-8AOC-BBN as a leading candidate, having enhanced tumor uptake and favorable pharmacokinetics in tumor-bearing mice. These investigations advance structure–activity relationship understanding and support heterobivalent radiopharmaceuticals for precision imaging and targeted prostate cancer therapy.
- 5 December 2025
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 152-153, 109596
PET imaging of [64Cu]copper(II) chloride and tetrathiomolybdate administration in animal models of triple-negative breast cancer
- 5 December 2025
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 152-153, 109596
PET imaging of [64Cu]copper(II) chloride and tetrathiomolybdate administration in animal models of triple-negative breast cancer
- Open Access
- 14 July 2024
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 136-137, 108938
Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen
- 14 July 2024
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 136-137, 108938
Open AccessEvaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen
- 16 October 2018
- Published by Springer Nature
- Vol. 1126, 135-158
Peptide-Based Radiopharmaceuticals for Molecular Imaging of Prostate Cancer
Given the high incidence of prostate cancer, there is a continuing need for advances in early detection and in effective treatments. Over the last several years, radiolabeled peptides have been developed, which can target receptors on prostate tumors with high affinity and specificity. These peptides are eliminated from normal tissues rapidly, producing high contrast for PET and SPECT imaging. Receptors of interest for tumor imaging include prostate specific membrane antigen (PSMA), gastrin-releasing peptide receptor (GRPR), and αvβ3 integrin. Because radiolabeled peptides afford high tumor-to-normal tissue uptake ratios, the potential of peptide-based targeted radiotherapy of prostate cancer is being explored. In addition, targeting either of two receptors with one peptide may allow more tumors to be detected and aid in the delineation of early versus advanced disease. Taken together, all these developments in peptide-based imaging and therapy of prostate cancer offer the promise of personalized, molecular medicine for individual patients.
- 16 October 2018
- Published by Springer Nature
- Vol. 1126, 135-158
Peptide-Based Radiopharmaceuticals for Molecular Imaging of Prostate Cancer
Given the high incidence of prostate cancer, there is a continuing need for advances in early detection and in effective treatments. Over the last several years, radiolabeled peptides have been developed, which can target receptors on prostate tumors with high affinity and specificity. These peptides are eliminated from normal tissues rapidly, producing high contrast for PET and SPECT imaging. Receptors of interest for tumor imaging include prostate specific membrane antigen (PSMA), gastrin-releasing peptide receptor (GRPR), and αvβ3 integrin. Because radiolabeled peptides afford high tumor-to-normal tissue uptake ratios, the potential of peptide-based targeted radiotherapy of prostate cancer is being explored. In addition, targeting either of two receptors with one peptide may allow more tumors to be detected and aid in the delineation of early versus advanced disease. Taken together, all these developments in peptide-based imaging and therapy of prostate cancer offer the promise of personalized, molecular medicine for individual patients.
- Open Access
- 1 January 2018
- Published by SAGE Publications in Molecular Imaging
- Vol. 17
Evaluation of a Tumor-Targeting, Near-Infrared Fluorescent Peptide for Early Detection and Endoscopic Resection of Polyps in a Rat Model of Colorectal Cancer
The goal of these studies was to use a tumor-targeting, near-infrared (NIR) fluorescent peptide to evaluate early detection and to guide surgical removal of polyps in a genetically engineered rat model of spontaneous colorectal cancer. This peptide, LS301, was conjugated to Cy7.5 and applied topically to the colon of adenoma-bearing Pirc rats. Ten minutes after administration, rats underwent targeted NIR laser colonoscopy. Rats were also evaluated by white light colonoscopy and narrow-band imaging, for comparison to the NIR technique. Unlike white light and narrow-band colonoscopy, NIR imaging detected unexpected flat lesions in young Pirc rats. NIR imaging was also used to assess resection margins after electrocauterization of polyps. Tumor margins remained negative at 5 weeks postsurgery, demonstrating successful polypectomy. The present studies show that NIR-targeted colonoscopy is an attractive strategy to improve screening for and resection of colorectal neoplasia.
- 1 January 2018
- Published by SAGE Publications in Molecular Imaging
- Vol. 17
Open AccessEvaluation of a Tumor-Targeting, Near-Infrared Fluorescent Peptide for Early Detection and Endoscopic Resection of Polyps in a Rat Model of Colorectal Cancer
The goal of these studies was to use a tumor-targeting, near-infrared (NIR) fluorescent peptide to evaluate early detection and to guide surgical removal of polyps in a genetically engineered rat model of spontaneous colorectal cancer. This peptide, LS301, was conjugated to Cy7.5 and applied topically to the colon of adenoma-bearing Pirc rats. Ten minutes after administration, rats underwent targeted NIR laser colonoscopy. Rats were also evaluated by white light colonoscopy and narrow-band imaging, for comparison to the NIR technique. Unlike white light and narrow-band colonoscopy, NIR imaging detected unexpected flat lesions in young Pirc rats. NIR imaging was also used to assess resection margins after electrocauterization of polyps. Tumor margins remained negative at 5 weeks postsurgery, demonstrating successful polypectomy. The present studies show that NIR-targeted colonoscopy is an attractive strategy to improve screening for and resection of colorectal neoplasia.
- 20 January 2016
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 55 (3) , 1124-1133
Synthesis, Characterization, and In Vitro Evaluation of New 99mTc/Re(V)-Cyclized Octreotide Analogues: An Experimental and Computational Approach
Radiolabeled proteolytic degradation-resistant somatostatin analogues have been of long-standing interest as cancer imaging and radiotherapy agents for targeting somatostatin receptor-positive tumors. Our interest in developing 186Re- and 188Re-based therapeutic radiopharmaceuticals led to investigation of a new Re(V)-cyclized octreotide analogue, Re(V)-cyclized, thiolated-DPhe1-Cys2-Tyr3-DTrp4-Lys5-Thr6-Cys7-Thr(OH)8 (Re-SDPhe-TATE) using both experimental and quantum chemical methods. The metal is directly coordinated to SDPhe-TATE through cyclization of the peptide around the [ReO]3+ core. Upon complexation, four isomers were observed; the isolated/semi-isolated isomers exhibited different somatostatin receptor (sstr) binding affinities, 0.13 to 1.5 μM, in rat pancreatic tumor cells. Two-dimensional NMR experiments and electronic structure calculations were employed to elucidate the structural differences among the different isomers. According to NMR studies, the metal is coordinated to three thiolates and the backbone amide of Cys2 in isomers 1 and 4, whereas the metal is coordinated to three thiolates and the backbone amide of Tyr3 in isomer 2. Quantum chemical methods clarified the stereochemistry of Re-SDPhe-TATE and the possible peptide arrangements around the [ReO]3+ core. The re-cyclization reaction was translated to the 99mTc radiotracer level with four isomers observed on complexation with comparable HPLC retention times as the Re-SDPhe-TATE isomers. About 85% total 99mTc labeling yield was achieved by ligand exchange from 99mTc-glucoheptonate at 60 °C for an hour. About 100% and 51% of 99mTc(V)-cyclized SDPhe-TATE remained intact in phosphate buffered saline and 1 mM cysteine solution under physiological conditions at 6 h, respectively.
- 20 January 2016
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 55 (3) , 1124-1133
Synthesis, Characterization, and In Vitro Evaluation of New 99mTc/Re(V)-Cyclized Octreotide Analogues: An Experimental and Computational Approach
Radiolabeled proteolytic degradation-resistant somatostatin analogues have been of long-standing interest as cancer imaging and radiotherapy agents for targeting somatostatin receptor-positive tumors. Our interest in developing 186Re- and 188Re-based therapeutic radiopharmaceuticals led to investigation of a new Re(V)-cyclized octreotide analogue, Re(V)-cyclized, thiolated-DPhe1-Cys2-Tyr3-DTrp4-Lys5-Thr6-Cys7-Thr(OH)8 (Re-SDPhe-TATE) using both experimental and quantum chemical methods. The metal is directly coordinated to SDPhe-TATE through cyclization of the peptide around the [ReO]3+ core. Upon complexation, four isomers were observed; the isolated/semi-isolated isomers exhibited different somatostatin receptor (sstr) binding affinities, 0.13 to 1.5 μM, in rat pancreatic tumor cells. Two-dimensional NMR experiments and electronic structure calculations were employed to elucidate the structural differences among the different isomers. According to NMR studies, the metal is coordinated to three thiolates and the backbone amide of Cys2 in isomers 1 and 4, whereas the metal is coordinated to three thiolates and the backbone amide of Tyr3 in isomer 2. Quantum chemical methods clarified the stereochemistry of Re-SDPhe-TATE and the possible peptide arrangements around the [ReO]3+ core. The re-cyclization reaction was translated to the 99mTc radiotracer level with four isomers observed on complexation with comparable HPLC retention times as the Re-SDPhe-TATE isomers. About 85% total 99mTc labeling yield was achieved by ligand exchange from 99mTc-glucoheptonate at 60 °C for an hour. About 100% and 51% of 99mTc(V)-cyclized SDPhe-TATE remained intact in phosphate buffered saline and 1 mM cysteine solution under physiological conditions at 6 h, respectively.
- 1 November 2015
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (11) , 809-815
Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma
- 1 November 2015
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (11) , 809-815
Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma
- 1 September 2015
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (9) , 704-710
Targeted antisense radiotherapy and dose fractionation using a 177Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate
- 1 September 2015
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (9) , 704-710
Targeted antisense radiotherapy and dose fractionation using a 177Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate
- 1 May 2012
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 73 (5) , 681-688
Evaluation of a B-cell leukemia-lymphoma 2-specific radiolabeled peptide nucleic acid–peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma
Objective—To evaluate use of a radiolabeled peptide nucleic acid–peptide conjugate (RaPP) targeting B-cell leukemia-lymphoma 2 (BCL2) mRNA for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma and to assess associations among RaPP uptake, time to tumor progression (TTP), and BCL2 mRNA expression. Animals—11 dogs with B-cell lymphoma and 1 clinically normal dog. Procedures—Scintigraphic images were acquired 1 hour after IV injection of the RaPP. Regions of interest (ROIs) were drawn around lymph nodes, liver, and spleen; ROI intensity (relative to that of an equally sized region of muscle in the same image) was measured. Each ROI was also subjectively categorized as positive or negative for increased RaPP uptake. Expression of BCL2 mRNA was determined via quantitative reverse transcriptase PCR assay of a lymph node sample from dogs with lymphoma. Associations among imaging results, TTP, and BCL2 mRNA expression were evaluated. Results—Increased RaPP uptake was detected in affected tissues of dogs with lymphoma. Dogs with superficial cervical lymph node ROIs categorized as negative (n = 8) for increased RaPP uptake had a significantly longer TTP than did dogs for which this ROI was considered positive (2). Measured intensity of mandibular and superficial cervical lymph node ROIs was negatively associated with TTP. Associations among BCL2 mRNA and ROI intensity or TTP were not significant. Conclusions and Clinical Relevance—Increased RaPP uptake at mandibular or superficial cervical lymph node ROIs may be a negative prognostic indicator in dogs with lymphoma. A larger investigation is needed to determine clinical value of the RaPP for disease detection and prognostication.
- 1 May 2012
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 73 (5) , 681-688
Evaluation of a B-cell leukemia-lymphoma 2-specific radiolabeled peptide nucleic acid–peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma
Objective—To evaluate use of a radiolabeled peptide nucleic acid–peptide conjugate (RaPP) targeting B-cell leukemia-lymphoma 2 (BCL2) mRNA for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma and to assess associations among RaPP uptake, time to tumor progression (TTP), and BCL2 mRNA expression. Animals—11 dogs with B-cell lymphoma and 1 clinically normal dog. Procedures—Scintigraphic images were acquired 1 hour after IV injection of the RaPP. Regions of interest (ROIs) were drawn around lymph nodes, liver, and spleen; ROI intensity (relative to that of an equally sized region of muscle in the same image) was measured. Each ROI was also subjectively categorized as positive or negative for increased RaPP uptake. Expression of BCL2 mRNA was determined via quantitative reverse transcriptase PCR assay of a lymph node sample from dogs with lymphoma. Associations among imaging results, TTP, and BCL2 mRNA expression were evaluated. Results—Increased RaPP uptake was detected in affected tissues of dogs with lymphoma. Dogs with superficial cervical lymph node ROIs categorized as negative (n = 8) for increased RaPP uptake had a significantly longer TTP than did dogs for which this ROI was considered positive (2). Measured intensity of mandibular and superficial cervical lymph node ROIs was negatively associated with TTP. Associations among BCL2 mRNA and ROI intensity or TTP were not significant. Conclusions and Clinical Relevance—Increased RaPP uptake at mandibular or superficial cervical lymph node ROIs may be a negative prognostic indicator in dogs with lymphoma. A larger investigation is needed to determine clinical value of the RaPP for disease detection and prognostication.
- 14 November 2011
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 22 (12) , 2444-2452
Comparison of Pretargeted and Conventional CC49 Radioimmunotherapy Using 149Pm, 166Ho, and 177Lu
The therapeutic efficacies of radiolabeled biotin, pretargeted by monoclonal antibody (mAb)–streptavidin fusion protein CC49 scFvSA, were compared to those of radiolabeled mAb CC49, using the three radiolanthanides in an animal model of human colon cancer. The purpose of the present study was to compare antibody pretargeting to conventional radioimmunotherapy using 149Pm, 166Ho, or 177Lu. Nude mice bearing LS174T colon tumors were injected sequentially with CC49 scFvSA, the blood clearing agent biotin-GalNAc16, and 149Pm-, 166Ho-, or 177Lu-DOTA-biotin. Tumor-bearing mice were alternatively administered 149Pm-, 166Ho-, or 177Lu-MeO-DOTA-CC49. Therapy with pretargeted 149Pm-,166Ho-, and 177Lu-DOTA-biotin increased the median time of progression to a 1 g tumor to 50, 41, and 50 days post-treatment, respectively. Therapy with 149Pm-,166Ho-, and 177Lu-MeO-DOTA-CC49 increased the median time to progression to 53, 24, and 67 days post-treatment, respectively. In contrast, saline controls showed a median time to progression of 13 days postinjection. Treatment with pretargeted 149Pm-, 166Ho-, and 177Lu-biotin or 149Pm-, 166Ho-, and 177Lu-CC49 increased tumor doubling time to 18–36 days, compared to 3 days for saline controls. Among treated mice, 23% survived >84 days post-therapy, and 11% survived 6 months, but controls survived 177Lu as an optimal radiolanthanide for future evaluation of these agents in toxicity and multiple-dose therapy studies.
- 14 November 2011
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 22 (12) , 2444-2452
Comparison of Pretargeted and Conventional CC49 Radioimmunotherapy Using 149Pm, 166Ho, and 177Lu
The therapeutic efficacies of radiolabeled biotin, pretargeted by monoclonal antibody (mAb)–streptavidin fusion protein CC49 scFvSA, were compared to those of radiolabeled mAb CC49, using the three radiolanthanides in an animal model of human colon cancer. The purpose of the present study was to compare antibody pretargeting to conventional radioimmunotherapy using 149Pm, 166Ho, or 177Lu. Nude mice bearing LS174T colon tumors were injected sequentially with CC49 scFvSA, the blood clearing agent biotin-GalNAc16, and 149Pm-, 166Ho-, or 177Lu-DOTA-biotin. Tumor-bearing mice were alternatively administered 149Pm-, 166Ho-, or 177Lu-MeO-DOTA-CC49. Therapy with pretargeted 149Pm-,166Ho-, and 177Lu-DOTA-biotin increased the median time of progression to a 1 g tumor to 50, 41, and 50 days post-treatment, respectively. Therapy with 149Pm-,166Ho-, and 177Lu-MeO-DOTA-CC49 increased the median time to progression to 53, 24, and 67 days post-treatment, respectively. In contrast, saline controls showed a median time to progression of 13 days postinjection. Treatment with pretargeted 149Pm-, 166Ho-, and 177Lu-biotin or 149Pm-, 166Ho-, and 177Lu-CC49 increased tumor doubling time to 18–36 days, compared to 3 days for saline controls. Among treated mice, 23% survived >84 days post-therapy, and 11% survived 6 months, but controls survived 177Lu as an optimal radiolanthanide for future evaluation of these agents in toxicity and multiple-dose therapy studies.